Evaluation of Brain Damage Due to Coronary Angioplasty in Percutaneous Intervention Patients
Launched by ONDOKUZ MAYIS UNIVERSITY · Feb 1, 2021
Trial Information
Current as of July 24, 2025
Completed
Keywords
ClinConnect Summary
This study was produced from the assistant's thesis and was previously accepted as a poster at EuroPCR 2020. We recently completed the full-length article.
This thesis study was supported by Ondokuzmayis University.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • CTO and Non-CTO patients undergoing percutaneous coronary intervention
- Exclusion Criteria:
- • baseline NSE elevation
- • acute coronary syndromes or cardiac surgery within 4 weeks
- • patients with a cerebrovascular accident
- • intracranial hemorrhage
- • and head trauma
- • central nervous system tumor
- • degenerative central nervous system disorders and neuroendocrine tumors
About Ondokuz Mayıs University
Ondokuz Mayıs University is a prestigious academic institution located in Turkey, renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its cutting-edge facilities and a multidisciplinary team of experts to conduct innovative studies that aim to enhance patient care and contribute to scientific knowledge. With a focus on ethical standards and rigorous methodologies, Ondokuz Mayıs University is dedicated to fostering collaborations that drive breakthroughs in healthcare, ultimately improving treatment outcomes and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Samsun, , Turkey
Patients applied
Trial Officials
Muhammet Uyanık, M.D.
Principal Investigator
Ondokuz Mayıs University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials